Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0R4ML
|
||||
| Former ID |
DIB002049
|
||||
| Drug Name |
P1A
|
||||
| Synonyms |
IPSAT P1A; P1A, Ipsat Therapies
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Toxicity [ICD10:T36-T50, T51-T65] | Discontinued in Phase 2 | [1] | ||
| Company |
Ipsat Therapies Oy
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C27H44O6
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Beta-lactamase | Target Info | Modulator | [2] | |
| References | |||||
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020134) | ||||
| REF 2 | IPSAT P1A, a class A beta-lactamase therapy for the prevention of penicillin-induced disruption to the intestinal microflora. Curr Opin Investig Drugs. 2009 Aug;10(8):838-44. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.